Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Caribou Biosciences (CRBU) Receivables - Net: 2020-2025

Historic Receivables - Net for Caribou Biosciences (CRBU) over the last 5 years, with Sep 2025 value amounting to $242,000.

  • Caribou Biosciences' Receivables - Net rose 31.52% to $242,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $242,000, marking a year-over-year increase of 31.52%. This contributed to the annual value of $265,000 for FY2024, which is 79.05% up from last year.
  • Caribou Biosciences' Receivables - Net amounted to $242,000 in Q3 2025, which was up 240.85% from $71,000 recorded in Q2 2025.
  • Caribou Biosciences' Receivables - Net's 5-year high stood at $1.5 million during Q1 2023, with a 5-year trough of $2,000 in Q2 2021.
  • For the 3-year period, Caribou Biosciences' Receivables - Net averaged around $505,636, with its median value being $242,000 (2025).
  • Its Receivables - Net has fluctuated over the past 5 years, first spiked by 26,100.00% in 2022, then tumbled by 90.40% in 2025.
  • Over the past 5 years, Caribou Biosciences' Receivables - Net (Quarterly) stood at $1.2 million in 2021, then plummeted by 82.48% to $202,000 in 2022, then decreased by 26.73% to $148,000 in 2023, then surged by 79.05% to $265,000 in 2024, then skyrocketed by 31.52% to $242,000 in 2025.
  • Its Receivables - Net stands at $242,000 for Q3 2025, versus $71,000 for Q2 2025 and $88,000 for Q1 2025.